PharmaCielo Ltd.
PCLOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $1 | $1 |
| % Growth | 275.3% | -57% | -51.1% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $1 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -30.3% | 4% | 15% | 42.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $0 | $0 | $1 |
| SG&A Expenses | $2 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $1 | $1 | $1 |
| Operating Income | -$2 | -$1 | -$1 | -$1 |
| % Margin | -203.8% | -253.8% | -146.2% | -50.7% |
| Other Income/Exp. Net | $1 | -$0 | -$1 | -$1 |
| Pre-Tax Income | -$1 | -$1 | -$2 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$2 | -$2 |
| % Margin | -111.9% | -403.4% | -286.6% | -133.3% |
| EPS | -0.005 | -0.005 | -0.009 | -0.009 |
| % Growth | -3.9% | 43.3% | -4.7% | – |
| EPS Diluted | -0.005 | -0.005 | -0.009 | -0.009 |
| Weighted Avg Shares Out | 188 | 188 | 175 | 175 |
| Weighted Avg Shares Out Dil | 188 | 188 | 175 | 175 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$1 | -$0 |
| % Margin | -27.3% | -135.4% | -138.4% | -37.5% |